Publications

Please contact us for more information.

1. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May 15;23(7):1013-8.

2. McKeown MJ, Uthama A, Abugharbieh R, Palmer S, Lewis M, Huang X. Shape (but not volume) changes in the thalami in Parkinson disease. BMC Neurol. 2008 Apr 16;8:8.

3. McKeown MJ, Li J, Huang X, Lewis MM, Rhee S, Young Truong KN, Wang ZJ. Local linear discriminant analysis (LLDA) for group and region of interest (ROI)-based fMRI analysis. Neuroimage. 2007 Sep 1;37(3):855-65. Epub 2007 May 26.

4. Huang X, Lee YZ, McKeown M, Gerig G, Gu H, Lin W, Lewis MM, Ford S, Troster AI, Weinberger DR, Styner M. Asymmetrical ventricular enlargement in Parkinson's disease. Mov Disord. 2007 Aug 15;22(11):1657-60. [Abstract via PubMed].

5. George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007 Jul;93(1-3):42-50. Epub 2007 Apr 30.

6. Lewis MM, Slagle CG, Smith AB, Truong Y, Bai P, McKeown MJ, Mailman RB, Belger A, Huang X. Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries. Neuroscience. 2007 Jun 15;147(1):224-35. Epub 2007 May 17. [Abstract via PubMed].

7. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord. 2007 Feb 15;22(3):377-81. [Abstract via PubMed].

8. Lewis MM, Huang X, Nichols DE, Mailman RB. 2006. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol. Disord. Drug Targets. 5(3):345-53. Review. [Abstract via PubMed].

 
9. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. 2006. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Movement Disorders (in press). [ Abstract via PubMed].

 
10. Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 63(2):189-93. [ Abstract via PubMed].

 
11. Huang X, Chen, P, and Poole C. 2004. ApoE e2 allele associated with higher prevalence of sporadic Parkinson's disease. Neurology 62:2198-2202 [ Abstract via PubMed].

 
12. Okun MS, Crucian GP, Fischer L, Walter BL, Testa CM, Vitek JL, DeLong MR, Hanfelt J, and Huang X. 2004. Testosterone deficiency in a Parkinson's disease clinic: results of a survey. J. Neurol. Neurosurg. Psychiatry. 75: 165-166. [ Abstract via PubMed].

 
13. Huang X, and Hall CD. 2003. Tremor. in Netter's Internal Medicine. (A. Greganti, M. Rungie, eds.) Icon Publications.

14. Mailman RB, Huang X, and Nichols DE . 2002. US Patent Application 20020132827 (published 09/19/2002 ) Method of treatment of dopamine-related dysfunction. [ Abstract via PatentStorm].

 
15. Mailman RB, Huang X, and Nichols DE . 2001. Dopamine D1 full agonists and Parkinson's disease. Current Opin Investig. Drugs 2(11) 1582-1591. [ Abstract via PubMed].

 
16. Huang X, Howard JF: 2001. Myasthenia gravis and vitiligo: five new cases. Journal of Clinical Neuromuscular Disease 2:173-175. [ Pdf via JCNMD].

 
17. Huang X, Lawler CP, Nichols DE , Lewis MM, and Mailman RB. 2001. Dopamine D1 Receptors. International Review of Neurobiology 48:66-138. [ Abstract via PubMed].

 
18. Cozzi NV , Frescas S, Marona-Lewicka D, Huang X and Nichols DE . 1998, Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol. Biochem. Behav. 59:709-715 [ Abstract via PubMed].

 
19. Nichols DE , Monte A, Huang X and Marona-Lewicka D. 1996. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain. Res. 73:117-119 [ Abstract via PubMed].

 
20. Oberlander R, Ramachandran PB, Johnson MP, Huang X and Nichols DE. 1995. Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. J. Med. Chem. 38(18):3593-3601 [ Abstract via PubMed].

 
21. Pfaff RC, Huang X, Marona-Lewicka D, Oberlander R, and Nichols DE. 1995. Lysergamides. NIDA Research Monograph [ Abstract via PubMed].

 
22. Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudesky GA, and Nash JF. 1994. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5HT2A/2C agonist. J. Med. Chem. 37:4346-4351 [ Abstract via PubMed].

 
23. Huang X, Marona-Lewicka D, Oberlander R, Pfaff RC, and Nichols DE . 1994. Drug discrimination and receptor binding studies of N-isopropyl-lysergamide derivatives. Pharmacol. Biochem. Behav. 47:667-673 [ Abstract via PubMed].

 
24. Sprague JJ, Huang X, Kenthasamy A, and Nichols DE . 1994. Attenuation of 3,4-methylenedioxylmethamphetamine (MDMA)-induced neurotoxicity with serotonin precursors tryptophan and L-hydroxytryptophan. Life Sci. 55:1193-1198 [ Abstract via PubMed].

 
25. Nichols DE , Marona-Lewicka D, Huang X and Michael P. Johnson. 1993. Novel serotonergic agents. Drug Design and Discovery. 9:229-312 [ Abstract via PubMed].

 
26. Huang X and Nichols DE . 1993. 5-HT2 receptor-mediated potentiation of dopamine synthesis and serotonergic neurotoxicity. Eur. J. Pharmacol. 238:291-296 [ Abstract via PubMed].

 
27. Huang X, Marona-Lewicka D, and Nichols DE . 1992. Para-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol. 229:31-38 [ Abstract via PubMed].

 
28. Tomaszewski Z, Johnson MP, Huang X, and Nichols DE. 1992. Benzofuran bioisosteres of hallucinogenic tryptamines. J. Med. Chem. 35:2061-2064. [ Abstract via PubMed].

29. Oberlander R, Pfaff RC, Johnson MP, Huang X and Nichols DE. 1992. Stereoselective LSD-like activity in d-lysergic acid amides of (R) and (S) -aminobutane. J. Med. Chem. 35:203-211 [ Abstract via PubMed].

 
30. Nichols DE, Snyder SE, Oberlander R, Johnson MP, and Huang X. 1991. 2,3-Dihydrobenzofuran Analogues of Hallucinogenic Phenethylamines, J. Med. Chem. 34:276-281 [ Abstract via PubMed].

 
31. Johnson MP, Huang X and Nichols DE. 1991. Serotonin Neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a non-neurotoxic methylenedixoymethamphetamine (MDMA) analogue. Pharmacol. Biochem. Behav. 40:915-922 [ Abstract via PubMed].

 
32. Huang X, Johnson MP and Nichols DE . 1991. Reduction in brain serotonin markers by a -ethyltryptamine (Monase). Eur. J. Pharmacol. 200:187-190 [ Abstract via PubMed].

33. Johnson MP, Huang X, Oberlander R, Nash J-F, and Nichols DE . 1990. Behavioral, biochemical and neurotoxicological actions of the a -ethyl homologue of p-chloroamphetamine. Eur. J. Pharmacol. 191:1-10 [ Abstract via PubMed].